April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma
November 21st 2013T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.
Read More
Nivolumab Plus Ipilimumab in Advanced Melanoma
November 20th 2013Concurrent nivolumab and ipilimumab produced “rapid and deep†responses in patients with advanced melanoma who took part in the first phase I trial to evaluate the PD-1-blocking antibody nivolumab, along with the CTLA-4-blocking antibody ipilimumab.
Read More
Results from Pooled Analysis Reinforces Survival Benefit from Ipilimumab
October 2nd 2013Results from a pooled analysis of survival data from 12 studies demonstrated long-term survival benefit in patients with metastatic or locally advanced or unresectable melanoma treated with ipilimumab (Yervoy).
Read More
High-Dose IL-2 May Benefit Brain Metastases in Melanoma
September 24th 2013High doses of interleukin-2 (IL-2) could be used to treat patients with melanoma whose disease has metastasized to the brain, potentially expanding options in a population facing a grim prognosis, according to researchers from Saint Louis University in Missouri.
Read More
FDA Grants Priority Review of Dabrafenib and Trametinib Combination
September 17th 2013The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.
Read More